Compare Stocks

Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.

Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Avita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. It offers regenerative products for the treatment of burns, chronic wounds, and aesthetics indications. The company's patented and proprietary collection and application technology provides treatment solutions derived from a patient's own skin. Its lead product, RECELL System, is used in the treatment of various skin defects, such as burns and plastic reconstructive procedures. The company also offers ReGenerCell for chronic wounds and ReNovaCell for the restoration of pigmentation. Avita Medical Limited is based in Valencia, California.

Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.